Year |
Citation |
Score |
2020 |
Manjunath Y, Porciani D, Mitchem JB, Suvilesh KN, Avella DM, Kimchi ET, Staveley-O'Carroll KF, Burke DH, Li G, Kaifi JT. Tumor-Cell-Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer. International Journal of Molecular Sciences. 21. PMID 32182935 DOI: 10.3390/Ijms21051872 |
0.313 |
|
2018 |
Liu D, Qi X, Manjunath Y, Kimchi ET, Ma L, Kaifi JT, Staveley-O'Carroll KF, Li G. Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer. Journal of Immunology Research and Therapy. 3: 115-123. PMID 30123861 |
0.36 |
|
2018 |
Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Fox T, Rockey DC, Schell TD, Kester M, Avella DM, Staveley-O'Carroll KF. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. PMID 29408569 DOI: 10.1053/J.Gastro.2017.10.050 |
0.313 |
|
2017 |
Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer. Oncoimmunology. 7: e1372079. PMID 29296523 DOI: 10.1080/2162402X.2017.1372079 |
0.357 |
|
2016 |
Qi X, Lam SS, Liu D, Kim DY, Ma L, Alleruzzo L, Chen W, Hode T, Henry CJ, Kaifi J, Kimchi ET, Li G, Staveley-O'Carroll KF. Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. Journal of Clinical & Cellular Immunology. 7. PMID 27656328 DOI: 10.4172/2155-9899.1000438 |
0.382 |
|
2012 |
Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (Baltimore, Md.). 55: 141-52. PMID 21898502 DOI: 10.1002/Hep.24652 |
0.341 |
|
2008 |
Ryan CM, Staveley-O'Carroll K, Schell TD. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 906-20. PMID 18832997 DOI: 10.1097/Cji.0B013E318189F155 |
0.376 |
|
2003 |
Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 171: 697-707. PMID 12847236 DOI: 10.4049/Jimmunol.171.2.697 |
0.33 |
|
2000 |
Ewend MG, Thompson RC, Anderson R, Sills AK, Staveley-O'Carroll K, Tyler BM, Hanes J, Brat D, Thomas M, Jaffee EM, Pardoll DM, Brem H. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 438-48. PMID 10916753 DOI: 10.1097/00002371-200007000-00007 |
0.389 |
|
1997 |
Ruff AL, Guarnieri FG, Staveley-O'Carroll K, Siliciano RF, August JT. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. The Journal of Biological Chemistry. 272: 8671-8. PMID 9079699 DOI: 10.1074/Jbc.272.13.8671 |
0.41 |
|
1996 |
Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Research. 56: 21-6. PMID 8548765 |
0.536 |
|
1995 |
Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proceedings of the National Academy of Sciences of the United States of America. 92: 11671-5. PMID 8524826 DOI: 10.1073/Pnas.92.25.11671 |
0.498 |
|
Show low-probability matches. |